Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBT Margin (2016 - 2025)

Historic EBT Margin for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to 168.27%.

  • Standard Biotools' EBT Margin fell 695600.0% to 168.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.97%, marking a year-over-year increase of 38600.0%. This contributed to the annual value of 79.29% for FY2024, which is 95100.0% down from last year.
  • Per Standard Biotools' latest filing, its EBT Margin stood at 168.27% for Q3 2025, which was down 695600.0% from 84.01% recorded in Q2 2025.
  • Standard Biotools' EBT Margin's 5-year high stood at 26.77% during Q4 2021, with a 5-year trough of 346.98% in Q2 2022.
  • For the 5-year period, Standard Biotools' EBT Margin averaged around 104.13%, with its median value being 70.73% (2023).
  • As far as peak fluctuations go, Standard Biotools' EBT Margin surged by 4749300bps in 2021, and later plummeted by -2900400bps in 2022.
  • Standard Biotools' EBT Margin (Quarter) stood at 26.77% in 2021, then crashed by -187bps to 76.88% in 2022, then grew by 8bps to 70.73% in 2023, then rose by 2bps to 69.15% in 2024, then tumbled by -143bps to 168.27% in 2025.
  • Its EBT Margin was 168.27% in Q3 2025, compared to 84.01% in Q2 2025 and 64.18% in Q1 2025.